Home » Newsletters » BioWorld Science

BioWorld Science

July 13, 2015

View Archived Issues

Anti-annexin II shows potential as a new biomarker for APS

Resverlogix closes license agreement, enters stock purchase agreement with Hepalink

Monopar partners with Cancer Research UK and Cancer Research Technology on HuATN-658

Allergan patents EP2 receptor agonists

Daiichi Sankyo describes LCAT activators

Sanofi reports dual GIPR/GLP-1R agonists

Sunovion Pharmaceuticals reports P2X4 negative modulators

Bristol-Myers Squibb presents HCV NS5B inhibitors

Epizyme and Celgene extend research collaboration

AstraZeneca divests global rights to Entocort

CB-5083 receives FDA orphan drug designation for multiple myeloma

FDA orphan drug designation granted to Rett's syndrome candidate sarizotan

Etodolac and propranolol combination receives U.S. orphan status for malignant glioma

Genentech's atezolizumab reduces tumor size in phase II urothelial bladder cancer study

sFLT-1 may enable early diagnosis of sickle cell nephropathy

FDA approves Rexulti for schizophrenia and major depressive disorder

Homocitrulline can differentiate acute and chronic renal failure

Canadian trial investigates novel tumor-targeted oncolytic virus vaccine

BioDiem and Griffith University receive grant to study targets of BDM-I

Galectin-3 may be a biomarker of cirrhosis severity

Imbruvica approved in E.U. for Waldenstrom's macroglobulinemia

The Scripps Research Institute to study environmental triggers for autoimmune disease

Novel hyaluronic acid eyedrops promote corneal tissue healing

Benitec acquires full rights to Hepbarna hepatitis B program

Novo Nordisk releases results from first phase IIIa study of semaglutide for type 2 diabetes

EyeGate licenses EGP-437 and delivery technology to Valeant

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...